CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
TAK-831 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02716987
NCT02716987Phase 1Completed
CompareCT.gov

A Phase 1, Open-Label, Positron Emission Tomography Study in Healthy Subjects to Determine D-Amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-Dose Oral Administration in Healthy Subjects

Neurocrine Biosciences·interventional·Posted Mar 23, 2016·Updated Jun 14, 2021

In Brief

A Phase 1 clinical trial evaluating TAK-831 and [18F]PGM299 for Healthy. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the relationship between TAK-831 dose, plasma exposure, extent and duration of brain D-amino acid oxidase (DAO) enzyme occupancy following single oral dosing of TAK-831 in healthy participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
CollaboratorsTakeda

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 23, 2016
Enrollment StartMar 21, 2016
Primary CompletionAug 30, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 10.3 years ago

Interventions

TAK-831drug

TAK-831 oral suspension.

[18F]PGM299drug

\[18F\]PGM299 injection